Advertisement

Topics

Grünenthal Company Profile

15:19 EDT 25th September 2016 | BioPortfolio

Grünenthal è una società farmaceutica indipendente, basata sulla ricerca con operazioni internazionali. E' sempre stata una società a capitale privato fin dalla sua fondazione nel 1946. I prodotti Grünenthal sono commercializzati in oltre 80 Paesi e il numero delle filiali è in continua crescita. Grünenthal occupa circa 4.800 persone a livello mondiale, persone che hanno dato un grande contributo per il successo della Società.L'ulteriore consolidamento attraverso una ricerca innovativa è una parte integrante della politica della nostra Società. L'ambizione di Grünenthal è quella di essere una società leader nella Ricerca e Sviluppo in campi selezionati: l'area dolore è la nostra competenza core.

Location

Via Correggio, 43
Milano
20149
Italy

Contact

Phone: 39-02-43051
Fax: 39-02-430555
Email: dg@grunenthal.com


News Articles [19 Associated News Articles listed on BioPortfolio]

Grünenthal gets rights to AstraZeneca’s Zurampic for Europe and Latin America

Anglo-Swedish pharma major AstraZeneca has entered into a licensing agreement with Grünenthal for the…

Helsinn links with Grünenthal for Akynzeo marketing in Chile

Privately-held Swiss drugmaker Helsinn and Grünenthal Group have signed an exclusive agreement for the…

Grünenthal Gains Europe, Latin America Rights to AstraZeneca's Zurampic

AstraZeneca said today it has granted exclusive rights to the gout-associated hyperuricemia drug Zurampic® (lesinurad) in Europe and Latin America to Grünenthal, in a licensing deal that co...

AstraZeneca licenses gout drug Zurampic to Grünenthal in Europe and Latin America

UK drugmaker AstraZeneca (LSE: AZN) on Thursday said it has entered into a licensing agreement worth up to $230 million giving Grünenthal GmbH rights to the gout drug Zurampic (lesinurad) in Eur...

AstraZeneca licenses gout drug Zurampic to Grünenthal

Grünenthal Announces Exclusive License Agreement for Commercialization of Innovative Surgical Glue in the EU and Latin America

AACHEN, Germany, May 11, 2016 /PRNewswire/ -- Agreement underpins Grünenthal's strategy to strengthen its portfolio for the European hospital market  The Grünenthal Group today anno...

AZ’s Gabriel Baertschi joins Grünenthal as CEO

He also becomes chairman of the corporate executive board

Grünenthal Appoints Gabriel Baertschi as Chairman of the Corporate Executive Board and Chief Executive Officer Effective October 1, 2016

AACHEN, Germany, June 7, 2016 /PRNewswire/ -- Swiss native Gabriel Baertschi follows Prof. Dr. Eric-Paul Pâques who retires after 23 years with the company Grünenthal Group today announce...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

Grünenthal

Grünenthal è una società farmaceutica indipendente, basata sulla ricerca con operazioni internazionali. E' sempre stata una società a capitale privato fin dalla sua fondazione nel 1946. I prodotti...

Gr?nenthal

Grünenthal GmbH

Nil

More Information about "Grünenthal" on BioPortfolio

We have published hundreds of Grünenthal news stories on BioPortfolio along with dozens of Grünenthal Clinical Trials and PubMed Articles about Grünenthal for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Grünenthal Companies in our database. You can also find out about relevant Grünenthal Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record